# Senolytics for Secondary Progressive MS

> **NCT07270120** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ohio State University** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Sclerosis (MS) Secondary Progressive

## Interventions

- **DRUG:** Dasatinib and quercetin

## Key facts

- **NCT ID:** NCT07270120
- **Lead sponsor:** Ohio State University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-01-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07270120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07270120, "Senolytics for Secondary Progressive MS". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07270120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*